Naunyn-Schmiedeberg's archives of pharmacology最新文献

{"title":"Chrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy.","authors":"Hao Luo, Sijian Lin, Hao Lv, Wen Tan, Junlong Zhong, Jiachao Xiong, ZhiMing Liu, Qin Wu, Ming Chen, Kai Cao","doi":"10.1007/s00210-024-03714-3","DOIUrl":"https://doi.org/10.1007/s00210-024-03714-3","url":null,"abstract":"<p><p>Chrysoeriol (CHE) is a naturally occurring compound with established anti-inflammatory and anti-tumor effects. This study examines its potential role in regulating osteoclast differentiation and activity, both of which are crucial for bone remodeling. Computational docking revealed high binding affinity between CHE and RANKL, specifically at the Lys-181 residue of RANKL, suggesting potential inhibitory interactions on osteoclastogenesis. In vitro assays confirmed CHE's non-toxic profile at concentrations below 20 μM and demonstrated a dose-dependent suppression of osteoclast differentiation. Notably, CHE treatment significantly reduced TRAP activity and bone resorption capacity in a dose-dependent manner. Furthermore, CHE markedly decreased ROS production by NOX-1 expression and modulated the NRF2/KEAP1 pathway to enhance ROS clearance. The compound also showed inhibitory effects on the NF-κB and MAPK signaling pathways, which are crucial for osteoclast activation. In an ovariectomized mouse model, administration of CHE mitigated bone loss, indicating its therapeutic potential in osteoporosis. Collectively, these findings establish CHE as a promising natural therapeutic agent for treating bone disorders characterized by excessive bone resorption, underscoring the need for further clinical investigation.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the efficacy of gliclazide encapsulated hydrogel in the preclinical mice model for atopic dermatitis.","authors":"Kalpana Mamale, Shalini Shukla, Priyanka Mahale, Akshada Mhaske, Ravinder K Kaundal, Rahul Shukla","doi":"10.1007/s00210-024-03741-0","DOIUrl":"https://doi.org/10.1007/s00210-024-03741-0","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic skin inflammatory ailment commonly observed in young children and adults. Various therapeutic modalities are already explored for mitigation of AD but for prolong application very few modalities are recommended. Considering these challenges, we have successfully developed gliclazide-loaded hydrogels using the physical dispersion method. For preclinical assessment, we developed a DNCB induced an AD-like phenotype in mice, characterized by increased dermatitis index, scratching interval, ear thickness and weight, spleen and lymph node enlargement, mast cell infiltration, and elevated oxidative stress. However, topical application of the GLZ hydrogel significantly improved these DNCB-induced symptoms. Mice treated with the GLZ hydrogel exhibited a marked reduction in inflammatory markers in histological evaluations. Specifically, there was a decrease in epidermal thickness and mast cell infiltration compared to the DNCB + Vehicle group. Additionally, the topical GLZ hydrogel attenuated the AD-like phenotype by reducing oxidative stress markers. Importantly, these therapeutic effects occurred without significantly affecting blood glucose levels, highlighting the safety of the topical GLZ hydrogel. These findings demonstrate the potential of GLZ-loaded hydrogels as an effective and safe topical treatment for alleviating the symptoms of AD by targeting oxidative stress and inflammation.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of circulating miR-182-3p, miR -382-3p and miR -93, miR -142-3p involved in tamoxifen resistance and sensitivity in luminal-subtype breast cancer patients: a case-control study.","authors":"Elmira Aboutalebi Vand Beilankouhi, Zohreh Sanaat, Mohammad Ali Hosseinpour Feizi, Amir Mehdizadeh, Reza Safaralizadeh","doi":"10.1007/s00210-024-03770-9","DOIUrl":"https://doi.org/10.1007/s00210-024-03770-9","url":null,"abstract":"<p><p>Breast cancer (BC) commonly expresses estrogen receptors (ERs); hence, endocrine therapy targeting ERs is considered an effective treatment. Tamoxifen (TAM) resistance is an essential clinical complication leading to cancer progression and metastasis. This study investigated MicroRNAs (miRNAs) potentially implicated in drug resistance (miR-182-3p, miR-382-3p) or sensitivity (miR-93, miR- 142- 3p). This study aimed to provide new insights into serum microRNA expression profiles in BC. This case-control study included patients with luminal-A BC who received TAM for approximately one year. The case and control groups included 40 patients with or without local recurrence or metastasis. The expression levels of miR-182-3p, miR-382-3p, miR-93, and miR-142-3p in plasma samples were measured using real-time PCR with target-specific primers. The multivariate model of miR-93 (p = 0.0002), miR-182-3p (p = 0.0002), and miR-382-3p (p = 0.0028) demonstrated higher predictive power for TAM resistance. The only significant association was observed between miR-382-3p expression and lymphovascular invasion (LVI) (p = 0.0314). Moreover, lower expression levels of miR-93 and miR-382-3p were observed in the TAM-sensitive group compared to the TAM-resistant counterparts (p = 0.0002 and p = 0.0028, respectively). In contrast, the expression level of miR-182-3p was significantly higher in the TAM-sensitive group compared to the TAM-resistant group (p = 0.0002). receiver operating characteristic (ROC) curve analysis also indicated the expression of miR-182-3p (p < 0.001; area under curve (AUC): 0.753), miR-382-3p (p = 0.0028; AUC: 0.697), and miR-93 (p < 0.001; AUC: 0.762) as predictive markers for TAM resistance. Multivariate models based on miR-182-3p, miR-382-3p, and miR-93 can predict the response to hormone therapy. Measuring these miRNAs is also recommended for patients with luminal-subtype BC undergoing TAM therapy.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic effects of sequential treatment with doxorubicin and zoledronic acid on anticancer effects in estrogen receptor-negative breast cancer cells.","authors":"Apisara Danpipat, Kitiya Rujimongkon, Patthamapon Adchariyasakulchai, Nanticha Wilawan, Wannarasmi Ketchart","doi":"10.1007/s00210-024-03737-w","DOIUrl":"https://doi.org/10.1007/s00210-024-03737-w","url":null,"abstract":"<p><p>Zoledronic acid (ZA), a bisphosphonate, is commonly used in breast cancer patients with bone metastases to treat hypercalcemia and osteolysis. Recent studies showed the anti-cancer effects of ZA in breast cancer. This study further explored the synergistic effects of sequential and nonsequential ZA and doxorubicin (DOX) administration on estrogen receptor (ER)-positive and -negative breast cancer cell lines. Anti-cancer and anti-invasion effects were evaluated using MTT and Matrigel invasion assays. The synergistic effects were analyzed using the Chou-Talalay method. The protein levels of invasive and angiogenic factors were assessed by western blot. ZA was found to inhibit the proliferation of ER-positive and -negative breast cancer cells in a concentration-dependent manner. When ZA and doxorubicin (DOX) were sequentially combined at nontoxic concentrations, synergistic effects were observed in sequential administrations with DOX followed by ZA only in ER-negative breast cancer cells. Conversely, the sequential and nonsequential treatments did not significantly differ in ER-positive breast cancer cells. Moreover, this sequential treatment significantly reduced cell invasion and MMP9, pNF-κB, and FGF2 protein levels in ER-negative cells. The results suggest that ZA potentially inhibits ER-negative cells by suppressing the canonical NF-κB pathway and its downstream proteins, MMP9 and FGF2. Furthermore, DOX pretreatment enhanced the ZA effect and increased cell sensitivity to ZA, leading to improved outcomes with lower concentrations and shorter drug exposure durations. When combined with DOX, ZA produced synergistic effects on cell proliferation and invasion when administered sequentially in ER-negative breast cancer cells.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term forecast for antibacterial drug consumption in Germany using ARIMA models.","authors":"Lilly Josephine Bindel, Roland Seifert","doi":"10.1007/s00210-024-03721-4","DOIUrl":"https://doi.org/10.1007/s00210-024-03721-4","url":null,"abstract":"<p><p>The increasing supply shortages of antibacterial drugs presents significant challenges to public health in Germany. This study aims to predict the future consumption of the ten most prescribed antibacterial drugs in Germany up to 2040 using ARIMA (Auto Regressive Integrated Moving Average) models, based on historical prescription data. This analysis also evaluates the plausibility of the forecasts. Our findings represent one of the first long-term national forecasts for antibacterial drug consumption. ARIMA(0,1,0), a random walk model with drift, is the best-fitting model to capture trends across all antibacterial drugs. While more complex models offer greater detail, they seem less suitable for long-term forecasting. In a short-term forecast of 5 and 10 years, predictions between significant models vary very little. Predictions indicate increasing DDD-prescriptions for amoxicillin, cefuroxime axetil, amoxicillin clavulanic acid, clindamycin, azithromycin, nitrofurantoin, and ciprofloxacin, while declines are forecasted for doxycycline, phenoxymethylpenicillin, and sulfamethoxazole-trimethoprim. The reliability of the predictions varies. Forecasts for azithromycin, phenoxymethylpenicillin, and sulfamethoxazole-trimethoprim are likely accurate, whereas uncertainties exist for doxycycline, amoxicillin clavulanic acid, nitrofurantoin, and ciprofloxacin, though general trends appear valid. Potential discrepancies may arise in the predictions for amoxicillin, cefuroxime axetil, and clindamycin. These forecasts highlight the urgent need for proactive healthcare planning to prevent future shortages, a problem underscored by recent supply disruptions in Germany. Future research should extend this analysis to the development of bacterial resistance and other frequently used drug classes.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restoration of miR-200 expression suppresses proliferation and mobility of pancreatic cancer cell.","authors":"Guiming Wang, Lifeng Pan, Rende Guo","doi":"10.1007/s00210-024-03717-0","DOIUrl":"https://doi.org/10.1007/s00210-024-03717-0","url":null,"abstract":"<p><p>A number of various human malignancies have been associated with abnormal microRNAs (miRNA) expression. There are evidence that miR-200 operates as both tumor suppressor and an onco-miR in a variety of tumors. In this study, we evaluated the effects of miR-200 on the proliferation and migration of pancreatic cancer cells, as well as the underlying molecular pathways. Clinical tissue samples were used to investigate the expression of miR-200 in pancreatic cancer and normal tissues, and the gene expression omnibus (GEO) database provided bioinformatics confirmation. Using the pCMV vector, miR-200 was transfected into PANC-1 pancreatic cancer cells. After transfection, expression of cancer-related genes (at the mRNA and protein levels) was evaluated. The miR-200-transfected pancreatic cancer cells' survival, invasion, migration, and apoptosis were also investigated. According to the bioinformatics analysis, decreased miR-200 expression was associated with a worse prognosis in pancreatic cancer patients. Moreover, low levels of miR-200 in pancreatic cancer tissues were approved. After transfection, pancreatic cancer cells exhibit a sustained increase in expression of miR-200, which inhibits cell viability, invasion, and migration. Additional investigations revealed that increasing expression of miR-200 increases the proportion of pancreatic cancer cells that endure apoptosis. Changes in the mRNA and protein expression of apoptosis- and metastasis-related genes may account for these findings. Our results indicate that miR-200 functions as a tumor suppressor in pancreatic cancer cells and that upregulating miR-200 levels may be a useful therapeutic strategy for pancreatic cancer patients to halt the progression of the illness.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the protective effect of cilostazol on acute lung injury-mediated inflammation and in silico molecular modelling studies of inflammatory signalling pathway: a repurposing study.","authors":"Pranaya L Misar, Kishor V Otari","doi":"10.1007/s00210-024-03734-z","DOIUrl":"https://doi.org/10.1007/s00210-024-03734-z","url":null,"abstract":"<p><p>Acute lung injury i.e. ALI and its serious form acute respiratory distress syndrome (ARDS) are incurable medical conditions associated with significant global mortality and morbidity. The objective of the present research was to repurpose cilostazol, an antiplatelet drug with anti-inflammatory, antioxidant and antiapoptotic effect, as a potential approach for treatment of ALI. Its multifaceted effects make it promising candidate but its mechanism against ALI remains elusive. Hence it is needed to elucidate its mechanism of action to revealed its therapeutic potential and improve its clinical outcomes. This study investigated the potential inflammatory therapeutic targets of cilostazol with its protective effect against lipopolysaccharide (LPS)-induced ALI. We have identified 10 inflammatory target proteins of cilostazol i.e. PDK1, RAC1, PTK6, KDR, EGFR, endothelin-I, caspase-3, TNF-α, NF-κB1/BTK, a TLR/IRAK4 by molecular docking and validated by in vivo evaluation to demonstrate its therapeutic efficacy. In vivo experiment was performed in two sets; first to determine cellular inflammation by analysing the biomarkers in both lung homogenate and bronchoalveolar fluid and second set to study lung edema with dexamethasone as a standard. Additionally, respiratory parameters, related mRNA expressions and histopathology was evaluated. Our results, molecular docking showed that cilostazol binds to identified inflammatory target proteins with the same binding affinity as that of experimental inhibitors. In vivo, downregulated oxidative stress, and inflammation i.e. attenuated the pulmonary edema and vascular leakage, release of inflammatory mediators i.e. IL-6, TNF-α, NO, C-reactive protein (CRP), lactate dehydrogenase (LDH) myeloperoxidase (MPO), Krebs von den Lungen 6 (KL-6), and the recruitment of inflammatory cells; downregulated the m-RNA gene expressions of tumour necrosis factor alpha (TNF-α), nuclear factor kappa B( NF-kB), Toll-like receptor 4 (TLR4), Janus kinase/signal transducer, and activator of transcription 3 (JAK and STAT3); and improved total lung capacity in LPS-challenged rats. These findings revealed the cilostazol's efficacy as promising therapeutic agent for ALI by inhibiting the NF-κB/TLR4/JAK-STAT3 signalling pathway.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway.","authors":"Meng Lv, Xiangrui Chen, Qiting Yang, Chushuan Huang, Yongbiao Lv, Tian Zhang, Junxiang Cai","doi":"10.1007/s00210-024-03729-w","DOIUrl":"https://doi.org/10.1007/s00210-024-03729-w","url":null,"abstract":"<p><p>Berberine (BBR) has been proved to inhibit the malignant progression of non-small cell lung cancer (NSCLC), but the underlying molecular mechanism still needs to be further revealed. NSCLC cells (A549 and H1299) were treated with BBR. CCK8 assay, colony formation assay, flow cytometry, TUNEL staining and transwell assay were used to examine cell proliferation, apoptosis and invasion. The levels of spindle pole body component 25 (SPC25) and NDC80 kinetochore complex component (NUF2) were detected by qRT-PCR or western blot. The interaction between SPC25 and NUF2 was confirmed by Co-IP assay and FISH assay. Xenograft tumors were constructed to assess the anti-tumor role of BBR in vivo. BBR inhibited NSCLC cell growth, invasion and glycolysis. SPC25 was upregulated in NSCLC tissues, and BBR could reduce SPC25 expression in NSCLC cells. SPC25 knockdown repressed NSCLC cell growth, invasion and glycolysis, and its overexpression also reversed the anti-tumor effect of BBR. SPC25 could interact with NUF2, and NUF2 overexpression abolished the inhibitory effect of SPC25 knockdown or BBR on NSCLC cell behaviors. In animal experiments, BBR could suppress NSCLC tumor growth by inhibiting SPC25/NUF2 axis in vivo. BBR mainly played an anti-NSCLC role by targeting SPC25/NUF2 axis, which provided a new idea for NSCLC treatment.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An extra pair of eyes: adopting innovative approaches to detect integrity issues in Naunyn-Schmiedeberg's Archives of Pharmacology.","authors":"Ruben A van Diest, Roland Seifert, Marcel A G van der Heyden","doi":"10.1007/s00210-024-03697-1","DOIUrl":"https://doi.org/10.1007/s00210-024-03697-1","url":null,"abstract":"<p><p>Scientific integrity has been increasingly challenged by scientific misconduct and paper mills, resulting in an increase in retractions. Naunyn-Schmiedeberg's Archives of Pharmacology has been significantly impacted by fraudulent submissions, resulting in numerous retractions. By analyzing retraction notes and utilizing a post-publication surveillance strategy, this editorial discusses how this journal continues to deal with problematic publications, uncovers image- and physiological-related integrity issues, and responds to fraudulent activity. By adopting innovative methods to detect integrity issues and transparently communicating our concerns, we aim to increase awareness among scientists and scientific journals.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resveratrol polysaccharide is less cytotoxicity and inhibits UVA-, UVB-, and tertiary-butyl hydroperoxide-induced injury in human keratinocytes.","authors":"Yasukazu Saitoh, Shizuka Kanawa, Tsugumi Nohara, Ryoko Yamaguchi, Arisa Wakita, Chinatsu Ikeda, Hiroki Hamada","doi":"10.1007/s00210-024-03749-6","DOIUrl":"https://doi.org/10.1007/s00210-024-03749-6","url":null,"abstract":"<p><p>Natural stilbene compounds, such as resveratrol and pterostilbene, have been focused on owing to their diverse biological activities associated with antioxidant, anti-inflammatory, and anti-aging properties. However, their low water solubility limits their advanced applications. In this study, we investigated the protective effects of selected stilbene compounds (resveratrol, oxyresveratrol, gnetol, piceatannol, and pterostilbene) and their water-soluble derivatives (piceid, resveratrol polysaccharide, pterostilbene trisaccharide, and pterostilbene polysaccharide) against UVA-, UVB irradiation, tertiary-butyl hydroperoxide (t-BuOOH)- and hydrogen peroxide (H₂O₂)-induced injury in human epidermal cells. Our results revealed the significantly greater cytoprotective effects of resveratrol polysaccharide against UVA-, UVB-, and t-BuOOH-induced injury compared to that recorded for other stilbenes. This effect was associated with the suppression of stress-induced intracellular reactive oxygen species (ROS) generation and lipid peroxidation; resveratrol polysaccharides were more effective than other antioxidants. However, the tested compounds could not inhibit H₂O₂-induced cell injury. Our results indicate that most stilbene derivatives can inhibit UV- and lipid hydroperoxide-induced cellular injury; moreover, resveratrol polysaccharide exhibits excellent protective effects through the suppression of ROS generation and lipid peroxidation. Overall, the poly-glycosylation of resveratrol enhances its effectiveness against UVA or UVB irradiation- and lipid peroxidation-induced injuries in human keratinocytes. Therefore, the resveratrol polysaccharide is proposed to be a novel effective cytoprotective candidate to be used as a cosmetic ingredient for protecting skin from stress-related damage.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}